The city of Cypress, Texas, currently has 2 active clinical trials seeking participants for Alzheimer's Disease research studies.
Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3)
NCT05980949
Recruiting
This is a Phase 3 global, multicenter, 52-week, open-label extension (OLE) rollover study for subjects completing study CN012-0026, CN012-0027 or CN012-0056. Subjects (randomized or non-randomized) who complete the 38-week CN012-0026 study, 14-week CN012-0027 study or 14-week CN012-0056 study will be eligible to enroll in CN012-0028. The primary objective of the study is to assess the long-term safety and tolerability of KarXT in subjects with psychosis associated with Alzheimer's Disease.
Gender:
ALL
Ages:
Between 55 years and 90 years
Trial Updated:
02/18/2025
Locations: Horizon Clinical Research: Gill Neuroscience, Cypress, Texas
Conditions: Psychosis Associated With Alzheimer's Disease
Register for Updates
A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-2)
NCT06126224
Recruiting
This is a Phase 3, randomized, double-blind, placebo-controlled, parallel group study to evaluate the safety and efficacy of KarXT in male and female subjects who are aged 55 to 90 years and have mild to severe Alzheimer's Disease (AD) with moderate to severe psychosis related to AD. The primary objective of the study is to evaluate the efficacy of KarXT compared with placebo in the treatment of subjects with psychosis associated with AD as measured by the Neuropsychiatric Inventory-Clinician (... Read More
Gender:
ALL
Ages:
Between 55 years and 90 years
Trial Updated:
02/18/2025
Locations: Horizon Clinical Research: Gill Neuroscience, Cypress, Texas
Conditions: Psychosis Associated With Alzheimer's Disease
Register for Updates